BACKGROUND: Pancreatic islet transplantation has shown great success in the treatment of diabetic patients. However, the required immunosuppressive therapy exposes patients to serious side effects. METHODS: We have designed a novel five-component/three-membrane capsule and encapsulation system to protect the transplanted islet cells from immune system attack while allowing the influx of molecules and nutrients necessary for cell function/survival and efflux of the desired cellular product, specifically insulin, for making recipients healthy. RESULTS: We transplanted encapsulated canine pancreatic islets into the peritoneal cavity of pancreatectomized canines. Transplantation normalized fasting blood glucose levels in nine out of nine dogs for up to 214 days with a single transplantation. Retransplantation was assessed in three animals and encapsulated islets were effective in providing fasting glycemic control after the initial transplantation had run its course. No immunosuppression or anti-inflammatory therapy was used. CONCLUSION: This advancement in transplantation may lead to an alternative approach for islet transplantation treatment for diabetic patients. This approach may also benefit patients suffering from other hormone deficiency diseases including liver disease and Parkinson's disease.
BACKGROUND:Pancreatic islet transplantation has shown great success in the treatment of diabeticpatients. However, the required immunosuppressive therapy exposes patients to serious side effects. METHODS: We have designed a novel five-component/three-membrane capsule and encapsulation system to protect the transplanted islet cells from immune system attack while allowing the influx of molecules and nutrients necessary for cell function/survival and efflux of the desired cellular product, specifically insulin, for making recipients healthy. RESULTS: We transplanted encapsulated caninepancreatic islets into the peritoneal cavity of pancreatectomized canines. Transplantation normalized fasting blood glucose levels in nine out of nine dogs for up to 214 days with a single transplantation. Retransplantation was assessed in three animals and encapsulated islets were effective in providing fasting glycemic control after the initial transplantation had run its course. No immunosuppression or anti-inflammatory therapy was used. CONCLUSION: This advancement in transplantation may lead to an alternative approach for islet transplantation treatment for diabeticpatients. This approach may also benefit patients suffering from other hormone deficiency diseases including liver disease and Parkinson's disease.
Authors: Stephen Harrington; Janette Williams; Sonia Rawal; Karthik Ramachandran; Lisa Stehno-Bittel Journal: Tissue Eng Part A Date: 2017-03-02 Impact factor: 3.845
Authors: John Patrick McQuilling; Sivanandane Sittadjody; Rajesh Pareta; Samuel Pendergraft; Clancy J Clark; Alan C Farney; Emmanuel C Opara Journal: Methods Mol Biol Date: 2017
Authors: Emmanuel C Opara; Sayed-Hadi Mirmalek-Sani; Omaditya Khanna; Monica L Moya; Eric M Brey Journal: J Investig Med Date: 2010-10 Impact factor: 2.895
Authors: Duo An; Alan Chiu; James A Flanders; Wei Song; Dahua Shou; Yen-Chun Lu; Lars G Grunnet; Louise Winkel; Camilla Ingvorsen; Nicolaj Strøyer Christophersen; Johannes Josef Fels; Fredrik Wolfhagen Sand; Yewei Ji; Ling Qi; Yehudah Pardo; Dan Luo; Meredith Silberstein; Jintu Fan; Minglin Ma Journal: Proc Natl Acad Sci U S A Date: 2017-12-26 Impact factor: 11.205
Authors: D Jacobs-Tulleneers-Thevissen; M Chintinne; Z Ling; P Gillard; L Schoonjans; G Delvaux; B L Strand; F Gorus; B Keymeulen; D Pipeleers Journal: Diabetologia Date: 2013-04-26 Impact factor: 10.122
Authors: J P McQuilling; J Arenas-Herrera; C Childers; R A Pareta; O Khanna; B Jiang; E M Brey; A C Farney; E C Opara Journal: Transplant Proc Date: 2011-11 Impact factor: 1.066